Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD

摘要

Long-term ICS monotherapy is not recommended; however, long-term ICS treatment may be considered in association with LABAs for patients with a history of exacerbations despite appropriate treatment with LABAs and those with a peripheral eosinophil count > 300 [2]. An ICS combined with a LABA (e.g., FP/salmeterol in a dry powder inhaler) is more effective than either component alone in providing improved lung function and health status, as well as in reducing exacerbations in patients with moderate-to-very-severe COPD [2].